WO2021083191A1 - Kératine bd-2, son procédé de préparation, composition pharmaceutique la comprenant et son utilisation - Google Patents

Kératine bd-2, son procédé de préparation, composition pharmaceutique la comprenant et son utilisation Download PDF

Info

Publication number
WO2021083191A1
WO2021083191A1 PCT/CN2020/124327 CN2020124327W WO2021083191A1 WO 2021083191 A1 WO2021083191 A1 WO 2021083191A1 CN 2020124327 W CN2020124327 W CN 2020124327W WO 2021083191 A1 WO2021083191 A1 WO 2021083191A1
Authority
WO
WIPO (PCT)
Prior art keywords
keratin
protein
solution
nucleic acid
host cell
Prior art date
Application number
PCT/CN2020/124327
Other languages
English (en)
Chinese (zh)
Inventor
庾石山
王晓良
屈晶
史国茹
李密
王玲
蔡杰
李江
Original Assignee
中国医学科学院药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国医学科学院药物研究所 filed Critical 中国医学科学院药物研究所
Publication of WO2021083191A1 publication Critical patent/WO2021083191A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a keratin BD-2, a nucleic acid molecule encoding keratin BD-2, an expression vector containing the nucleic acid molecule, and a host cell containing the expression vector or genome integrating the nucleic acid molecule, and keratin BD-2
  • the preparation method of the keratin-containing pharmaceutical composition, and the keratin and the pharmaceutical composition are used in the preparation of antipyretic and analgesic, antitussive and expectorant, anticonvulsant, antiepileptic, hypotensive, anti-inflammatory, and anti-inflammatory Application of viral drugs.
  • Keratin is a kind of protein, which is widely found in the epidermis of humans and animals, and is the main component of hair, feathers, hoofs, shells, claws, horns, etc. It is a very important structural protein for connective tissue and plays a role in protecting the body. .
  • Keratin is widely present in organisms and is a renewable resource with great utilization value, but it has not been widely and effectively used. The main reason is that keratin is insoluble in various solvents, and keratin is generally more resistant to enzymatic hydrolysis by proteases than other proteins. Therefore, it is very difficult to extract and prepare natural keratin.
  • the technical problem solved by the present invention is to provide a keratin BD-2, a nucleic acid molecule encoding keratin BD-2, an expression vector containing the nucleic acid molecule, and a host cell containing the expression vector or genome integrating the nucleic acid molecule, and
  • the preparation method of keratin BD-2, the pharmaceutical composition containing keratin BD-2, and the above-mentioned keratin BD-2, nucleic acid molecule, expression vector, host cell, or pharmaceutical composition are used in the preparation of antipyretic, analgesic and antitussive Application in expectorant, anticonvulsant, antiepileptic, blood pressure lowering, anti-inflammatory, and antiviral drugs.
  • the present invention provides the following technical solutions:
  • the first aspect of the technical solution of the present invention is to provide a keratin BD-2, characterized in that the amino acid sequence of the keratin BD-2 is:
  • amino acid sequence shown in SEQ ID NO. 1 in the sequence list is formed by substitution, deletion or addition of 1-35 amino acids to form an amino acid sequence that basically maintains the same biological function.
  • keratin BD-2 conventional modification can be carried out on keratin BD-2; or a label useful for detection or purification can be attached to keratin BD-2.
  • the conventional modifications include acetylation, amidation, cyclization, glycosylation, phosphorylation, alkylation, biotinylation, fluorescent group modification, polyethylene glycol PEG modification, immobilization modification, Sulfation, oxidation, methylation, deamination, formation of disulfide bonds or disulfide bond breakage;
  • the tags include His6, GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc, Profinity eXact .
  • the second aspect of the technical solution of the present invention is to provide a nucleic acid molecule encoding the keratin BD-2 of the first aspect.
  • nucleic acid molecule is:
  • the third aspect of the technical solution of the present invention provides an expression vector, which is characterized in that the expression vector contains the nucleic acid molecule described in the second aspect.
  • the expression vector can be pET series, pUC series, pQE series, pBV series, pMAL series, pPIC9, pPIC9K, pHIL-S1, pPICZ ⁇ /A, pYAM75P, pHIL-D2, pA0815, pPIC3K, pPICZ, pHWO10, pGAPZ, pGAPZa, pPIC3.5K, etc.; the preferred expression vector is the pET series vector; the most preferred expression vector is pET-28a(+).
  • the fourth aspect of the technical solution of the present invention provides a host cell, characterized in that the host cell contains the expression vector of the third aspect or the nucleic acid molecule of the second aspect is integrated into the genome.
  • the host cell includes bacteria, yeast, Aspergillus, plant cells, or insect cells.
  • bacteria include Escherichia coli or yeast.
  • Competent host cells can be BL21 series, Transetta series, Rosetta series, DH5 ⁇ series, JM series, Top series, Orgami series, Trans1-T1, TG1, TB1; Y11430, MG1003, GS115 (AOX1), KM71, SMD1168, etc.; preferably The expression competent cells are BL21 (DE3), Transetta (DE3).
  • the fifth aspect of the technical solution of the present invention provides a method for preparing the keratin BD-2 of the first aspect, which is characterized in that it comprises the following steps:
  • step B Separating, purifying and drying the crude protein solution expressed in step A to obtain keratin BD-2.
  • the host cells are mainly selected from Escherichia coli, the keratin BD-2 is expressed in Escherichia coli inclusion bodies, and the fermentation equipment includes a shaker flask or a fermentation tank.
  • step A after the expression of keratin BD-2 is induced, the impurities can be washed with a cleaning agent and dissolved in a solution to obtain a crude protein solution.
  • the medium in step A may be LB medium, TB medium, SB medium, SOB medium, SOC medium, PDA medium, YPD medium, red bengal medium, high salt Chashi medium , DOBA medium, rice koji medium and its modified formula, etc.; shake flask fermentation preferably LB medium, TB medium, most preferably TB medium; fermenter preferably LB medium and its modified formula.
  • the inducer in step A can be IPTG, lactose, arabinose, etc.; preferably, IPTG, lactose.
  • step A the obtained fermentation broth is centrifuged, and the supernatant is discarded; the precipitate is suspended in the buffer, the cells are broken, and then centrifuged to discard the supernatant; the precipitate is washed with a cleaning agent, and then used The urea solution is dissolved to obtain a crude protein solution of BD-2.
  • the separation and purification method includes ultrafiltration microfiltration membrane technology purification method, column chromatography purification method, salting out method, and dialysis method.
  • step B the separation and purification method is as follows:
  • the dialysis method that is, the crude protein solution obtained in step A is purified by a dialysis method to obtain the target protein BD-2 solution.
  • the molecular weight cut-off of the dialysis bag can be 0.5-10 kD, the preferred molecular weight cut-off of the dialysis bag is 3.5-10 kD, and the most preferred molecular weight cut-off of the dialysis bag is 10 kD.
  • the ultrafiltration and microfiltration method that is, the crude protein solution obtained in step A is purified by membrane technology such as ultrafiltration membrane or microfiltration membrane to obtain a concentrated solution of the target protein BD-2.
  • the microfiltration membrane purification is performed twice, the pore size of the first membrane is 1000-1500 nm, and the pore size of the second membrane is 20-50 nm.
  • the column chromatography method that is, the crude protein solution obtained in step A is separated and purified by column chromatography, such as various exchange columns or exclusion column chromatography, to obtain the target protein BD-2.
  • the preferred exclusion column is a dextran gel column, Superdex 30 Increase, Superdex 75 Increase, Superdex 200 Increase, Superose 6 Increase, etc.
  • the preferred exchange column is an ion exchange resin column: anion exchange resin column, HiTrap Q FF, HiTrap Capto Q ImpRes, Capto Q ImpRes, HiTrap Capto Q, HiTrap DEAE, Toyopearl Q-650M, Toyopearl SuperQ-650M, etc.; cation exchange resin column, HiTrap SP FF, HiTrap Capto SP ImpRes, CaptoSP, Impopearl, HiT -650M, Toyopearl Super SP-650M.
  • the most preferred is an anion exchange resin column.
  • the eluents commonly used in the art can be used, such as water, salt solutions, and the salt solutions include sodium chloride solution, sodium dihydrogen phosphate solution, disodium hydrogen phosphate solution, sodium acetate, acetic acid, and the like.
  • the salting-out method is to purify the crude protein solution obtained in step A by salting-out method to obtain the target protein BD-2 suspension.
  • the salting-out agent can be ammonium sulfate, sodium sulfate, sodium chloride, magnesium chloride, aluminum sulfate, ammonium nitrate, ammonium chloride, magnesium sulfate, and the like.
  • the preferred salting-out agent is ammonium sulfate and its aqueous solution. A saturated aqueous ammonium sulfate solution is added to make the final concentration of ammonium sulfate reach 10-50%, preferably 20-30%, more preferably 25%.
  • the number of salting out is 1 to 3 times, preferably 2 times.
  • the precipitate is washed with pure water, and the washing frequency is 2 to 5 times, preferably 3 times.
  • the target protein BD-2 solution purified in step B can be freeze-dried or vacuum-dried into a dry powder, or the concentrated solution can be directly spray-dried into a dry powder.
  • the sixth aspect of the technical solution of the present invention provides a pharmaceutical composition, characterized in that the pharmaceutical composition contains the keratin BD-2 described in the first aspect or the nucleic acid molecule described in the second aspect or the first aspect
  • the expression vector of the third aspect or the host cell of the fourth aspect and a pharmaceutically acceptable carrier or excipient is provided.
  • the keratin obtained in the above steps of the present invention can be freeze-dried or vacuum-dried into a dry powder, or the concentrated liquid can be directly spray-dried into a dry powder, and then made into various dosage forms.
  • the present invention relates to a pharmaceutical composition, comprising any keratin obtained in the above steps and a pharmaceutically acceptable carrier.
  • the present invention also relates to a pharmaceutical composition containing the keratin of the present invention as an active ingredient and conventional pharmaceutical excipients or adjuvants.
  • the keratin of the present invention accounts for 0.1-100.0% of the total weight of the pharmaceutical composition.
  • the present invention also provides a pharmaceutical composition, which includes a pharmaceutical effective dose of protein as an active ingredient and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition of the present invention can be prepared according to methods known in the art.
  • the protein of the present invention can be combined with one or more solid or liquid pharmaceutical excipients and/or adjuvants to prepare an appropriate administration form or dosage that can be used as human or veterinary medicine. form.
  • the keratin of the present invention or the pharmaceutical composition containing it can be administered in a unit dosage form, and the route of administration can be enteral or parenteral, such as oral, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs, skin, vagina, For peritoneal, rectal, etc., oral administration is preferred.
  • the keratin protein of the present invention or the pharmaceutical composition containing it can be administered by injection.
  • Injections include intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, intraperitoneal injection, and acupoint injection.
  • the dosage form for administration may be a liquid dosage form, a solid dosage form or a semi-solid dosage form.
  • Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including oil-in-water, water-in-oil and double emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops Lotion, nasal drops, lotion and liniment, etc.
  • the solid dosage form can be tablets (including ordinary tablets, enteric-coated tablets, buccal tablets, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, and enteric-coated capsules), granules Preparations, powders, pellets, dripping pills, suppositories, films, patches, air (powder) sprays, sprays, etc.; semi-solid dosage forms can be ointments, gels, pastes, etc.
  • the keratin of the present invention can be made into ordinary preparations, slow-release preparations, controlled-release preparations, targeted preparations and various particle delivery systems.
  • diluents can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.
  • the humectant can be water, ethanol, iso Propanol, etc.
  • the binder can be starch syrup, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia syrup, gelatin syrup, sodium carboxymethyl cellulose, methyl cellulose, hypromellose Base cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene dipropanol, etc.
  • disintegrant can be dry starch, micro
  • the tablets can also be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
  • carriers In order to make the administration unit into a pill, various carriers known in the art can be widely used.
  • carriers are, for example, diluents and absorbents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, polyethylene glycol laurate, kaolin, talc, etc.; binders, such as Gum arabic, xanthan gum, gelatin, ethanol, honey, liquid sugar, rice paste or batter, etc.; disintegrants, such as agar powder, dried starch, alginate, sodium lauryl sulfonate, methyl cellulose, Ethyl cellulose and so on.
  • diluents and absorbents such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, polyethylene glycol laurate, kaolin, talc, etc.
  • binders such as Gum arabic, xanthan gum, ge
  • various carriers known in the art can be widely used.
  • carriers are, for example, polyethylene glycol, lecithin, cocoa butter, higher alcohols, higher alcohol esters, gelatin, semi-synthetic glycerides and the like.
  • the active ingredient of the keratin of the present invention is mixed with the above-mentioned various carriers, and the mixture thus obtained is placed in a hard gelatin capsule or a soft capsule.
  • the active ingredient keratin of the present invention can also be made into microcapsules, suspended in an aqueous medium to form a suspension, or filled into hard capsules or made into injections for application.
  • the keratin of the present invention is prepared into injection preparations, such as solutions, suspension solutions, emulsions, and lyophilized powder injections.
  • injection preparations such as solutions, suspension solutions, emulsions, and lyophilized powder injections.
  • Such preparations may be aqueous or non-aqueous, and may contain one and/or more A pharmacologically acceptable carrier, diluent, binder, lubricant, preservative, surfactant or dispersant.
  • the diluent can be selected from water, ethanol, polyethylene glycol, 1,3-propanediol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters and the like.
  • an appropriate amount of sodium chloride, glucose or glycerin can be added to the injection preparation, and in addition, conventional solubilizers, buffers, pH adjusters, etc. can also be added. These auxiliary materials are commonly used in this field.
  • coloring agents can also be added to the pharmaceutical preparations.
  • the keratin or pharmaceutical composition of the present invention can be administered by any known administration method.
  • the dosage of the keratin pharmaceutical composition of the present invention depends on many factors, such as the nature and severity of the disease to be prevented or treated, the gender, age, weight, personality and individual response of the patient or animal, the route of administration, and the number of administrations. , The purpose of treatment, so the therapeutic dose of the present invention can have a wide range of changes. Generally speaking, the dosage of the pharmaceutical ingredients of the present invention is well known to those skilled in the art. Appropriate adjustments can be made according to the actual amount of the drug contained in the final preparation of the keratin composition of the present invention to achieve the requirement of the therapeutically effective amount, and to accomplish the prevention or treatment purpose of the present invention.
  • the appropriate daily dosage range of keratin of the present invention is 0.01-500 mg/kg body weight, preferably 0.5-100 mg/kg body weight, more preferably 1-50 mg/kg body weight, and most preferably 2- 30mg/kg body weight.
  • the above-mentioned dosage can be administered in a single dosage form or divided into several, for example, two, three or four dosage forms, depending on the clinical experience of the administering doctor and the dosage regimen including the use of other treatment means.
  • the total dose required for each treatment can be divided into multiple or single doses.
  • the protein or pharmaceutical composition of the present invention can be taken alone, or combined with other therapeutic drugs or symptomatic drugs, and the dosage is adjusted.
  • the seventh aspect of the technical solution of the present invention provides the keratin BD-2 of the first aspect or the nucleic acid molecule of the second aspect or the expression vector of the third aspect or the host cell of the fourth aspect or Application of the pharmaceutical composition of the sixth aspect in the preparation of antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, antihypertensive, anti-inflammatory, and antiviral drugs.
  • the preparation of keratin BD-2 of the present invention includes the following steps:
  • the preferred nucleotide sequence is shown in SEQ ID No.2.
  • the expression vector can be pET series, pUC series, pQE series, pBV series, pMAL series, pPIC9, pPIC9K, pHIL-S1, pPICZ ⁇ /A, pYAM75P, pHIL-D2, pA0815, pPIC3K, pPICZ, pHWO10, pGAPZ, pGAPZa, pPIC3 .5K, etc.; the preferred expression vector is the pET series vector; the most preferred expression vector is pET-28a(+).
  • the host cell can be E. coli or yeast; the preferred host cell is E. coli;
  • Competent cells can be BL21 series, Transetta series, Rosetta series, DH5 ⁇ series, JM series, Top series, Orgami series, Trans1-T1, TG1, TB1; Y11430, MG1003, GS115 (AOX1), KM71, SMD1168, etc.; preferred
  • the expression competent cells are BL21 (DE3), Transetta (DE3).
  • the host cell will be fermented and cultured under appropriate conditions to induce the expression of the target protein BD-2;
  • Fermentation equipment can use shaker flasks or fermentation tanks;
  • the medium can be LB medium, TB medium, SB medium, SOB medium, SOC medium, PDA medium, YPD medium, red bengal medium, high salt Chashi medium, DOBA medium, rice koji Medium and its modified formula, etc.; LB medium and TB medium are preferred for shake flask fermentation, and TB medium is most preferred; LB medium and its modified formula are preferred for fermentation tanks.
  • the inducer can be IPTG, lactose, arabinose, etc.; preferably, IPTG, lactose.
  • Step (4) The obtained fermentation bacteria liquid is centrifuged, and the supernatant is discarded; the precipitate is suspended in the buffer, the cells are broken, and then centrifuged, and the supernatant is discarded; the precipitate is washed with a cleaning agent, and then dissolved with a urea solution , Get BD-2 crude protein solution.
  • the crude protein solution obtained in step (5) needs to be purified to obtain the target protein BD-2.
  • the purification can be performed by dialysis, or ultrafiltration and microfiltration, or column chromatography, or salting out steps.
  • the dialysis step that is, the crude protein solution obtained in step (5) is purified by a dialysis method to obtain the target protein BD-2 solution.
  • the molecular weight cut-off of the dialysis bag can be 0.5-10 kD, the preferred molecular weight cut-off of the dialysis bag is 3.5-10 kD, and the most preferred molecular weight cut-off of the dialysis bag is 10 kD.
  • the ultrafiltration and microfiltration step that is, the crude protein solution obtained in step (5) is purified by membrane technology such as ultrafiltration membrane or microfiltration membrane to obtain a concentrated solution of the target protein BD-2.
  • the microfiltration membrane purification is performed twice, the pore size of the first membrane is 1000-1500 nm, and the pore size of the second membrane is 20-50 nm.
  • the column chromatography step that is, the crude protein solution obtained in step (5) is passed through column chromatography, such as various exchange columns or exclusion column chromatography, to separate and purify the target protein BD-2.
  • the preferred exclusion column is a dextran gel column, Superdex 30 Increase, Superdex 75 Increase, Superdex 200 Increase, Superose 6 Increase, etc.
  • the preferred exchange column is an ion exchange resin column: anion exchange resin column, HiTrap Q FF, HiTrap Capto Q ImpRes, Capto Q ImpRes, HiTrap Capto Q, HiTrap DEAE, Toyopearl Q-650M, Toyopearl SuperQ-650M, etc.; cation exchange resin column, HiTrap SP FF, HiTrap Capto SP ImpRes, CaptoSP, Impopearl, HiT -650M, Toyopearl Super SP-650M.
  • the most preferred is an anion exchange resin column.
  • the eluents commonly used in the art can be used, such as water, salt solutions, and the salt solutions include sodium chloride solution, sodium dihydrogen phosphate solution, disodium hydrogen phosphate solution, sodium acetate, acetic acid, and the like.
  • the salting-out step that is, the crude protein solution obtained in step (5) is purified by salting-out method to obtain the target protein BD-2 suspension.
  • the salting-out agent can be ammonium sulfate, sodium sulfate, sodium chloride, magnesium chloride, aluminum sulfate, ammonium nitrate, ammonium chloride, magnesium sulfate, and the like.
  • the preferred salting-out agent is ammonium sulfate and its aqueous solution. A saturated aqueous ammonium sulfate solution is added to make the final concentration of ammonium sulfate reach 10-50%, preferably 20-30%, more preferably 25%.
  • the number of salting out is 1 to 3 times, preferably 2 times.
  • the precipitate is washed with pure water, and the washing frequency is 2 to 5 times, preferably 3 times.
  • the target protein BD-2 solution obtained by purification in steps A to D can be freeze-dried or vacuum dried into dry powder, or the concentrated solution can be directly spray-dried into dry powder.
  • the protein of the present invention is keratin obtained for the first time, and the preparation method of the present invention has the characteristics of high yield and high sample purity.
  • the pharmacodynamic test study of protein BD-2 on the fever model of SD rats induced by yeast and lipopolysaccharide proves that protein BD-2 can significantly inhibit the increase of body temperature at most time points after modeling. And has a strong effect;
  • the present invention uses protein BD-2 to test the effects of pilocarpine (PLO) and pentylenetetrazol (PTZ) on convulsions and epilepsy in mice, and proves that protein BD-2 can significantly prolong the level of epilepsy in mice. Onset latency
  • the present invention proves that protein BD-2 has a tendency to increase the excretion of phenol red and has the potential of expectorant effect through the experimental study of the effect of protein BD-2 on the expectorant of phenol red excretion method in mice;
  • the present invention proves that protein BD-2 can significantly reduce the number of writhing times in mice and has a significant analgesic effect.
  • Protein BD-2 crude solution A analyzed by reduced SDS-PAGE, the separation gel concentration was 12.5%, stained with Coomassie brilliant blue R250 method; a clear blue band was shown near the molecular weight of 45kD.
  • Example 1 an expression vector containing the sequence shown in SEQ ID No. 2 was obtained by synthesis and sequencing; the expression vector was transfected into BL21 (DE3) cells to obtain an expression competent host cell containing the target nucleotide sequence.
  • Kanamycin final concentration 50 ⁇ g/ml
  • LB medium Take 10ml of LB medium, add Kanamycin (final concentration 50 ⁇ g/ml), take a single colony on the plate and add it to LB medium, in a shaker, at 37°C, 220rpm conditions overnight expansion and culture for 15 hours to obtain seeds liquid.
  • Protein BD-2 crude solution B analyzed by reduced SDS-PAGE, the separation gel concentration was 12.5%, stained with Coomassie Brilliant Blue R250 method; a clear blue band was shown near the molecular weight of 45kD.
  • Example 1 an expression vector containing the sequence shown in SEQ ID No. 2 was obtained by synthesis and sequencing; the expression vector was transfected into BL21 (DE3) cells to obtain an expression competent host cell containing the target nucleotide sequence. Add the LB medium and incubate in a shaker at 37°C and 220 rpm for 1 hour to obtain a recombinant strain.
  • the bacterial solution was centrifuged at 7000 rpm for 5 minutes, and the supernatant was sterilized and discarded; the precipitate was suspended in about 200 ml buffer A, filtered with an 80-100 mesh screen, and the filtrate was crushed with a high-pressure crusher at a pressure of 800-1000 bar, twice, each 2 minutes each time. After crushing, the bacterial liquid was centrifuged at 7000 rpm for 30 minutes, and the supernatant was discarded.
  • Protein BD-2 crude solution C was analyzed by reduced SDS-PAGE, and the separation gel concentration was 12.5%, stained with Coomassie Brilliant Blue R250 method; a clear blue band was shown near the molecular weight of 45kD.
  • Example 4 Protein crude solution A was prepared by dialysis to obtain protein BD-2
  • Example 2 The crude protein solution A obtained in Example 1 was filtered with a 0.45 ⁇ m filter membrane, and the filtrate was combined. The filtrate was dialyzed with water, the dialysis bag had a molecular weight cutoff of 10kD, dialyzed for 72 hours, and the inner liquid was freeze-dried to obtain the target protein BD-2; the purity measured by electrophoresis was 97.1%.
  • the protein BD-2 solution was analyzed by reduced SDS-PAGE, the separation gel concentration was 12.5%, and it was stained with Coomassie Brilliant Blue R250. The molecular weight of BD-2 band is around 45kD.
  • Main materials Acetonitrile, formic acid, ammonium bicarbonate, dithiothreitol (DTT), iodoacetamide (IAA), trypsin, chymotrypsin, Glu-C, Asp-N;
  • Protein BD-2 undergoes pretreatments such as dissolution replacement, reductive alkylation, and multiple proteolysis to obtain digested peptides; the digested peptide solution is analyzed by liquid chromatography tandem mass spectrometry.
  • the original mass spectrometry file uses Maxquant (1.6.2.10 ) Search the protein database to analyze the data, and the identification result confirms that it is consistent with the target sequence SEQ ID No. 1.
  • Example 5 The crude protein solution A was purified by other methods to prepare protein BD-2
  • the crude protein solution A obtained in Example 1 was purified by the following two methods:
  • the first method salting out
  • the crude protein solution A is placed in a container with stirring for two salting out: slowly add ammonium sulfate saturated solution along the wall to make the final concentration of ammonium sulfate 25% or 50%.
  • the protein will precipitate during the salting out process, and wait until the salting out is complete.
  • Filter to complete the first salting out add 400ml of pure water to the precipitate to suspend, again slowly add a saturated solution of ammonium sulfate along the wall to make the final concentration of ammonium sulfate 25%, perform the second salting out, filter, the precipitation is Crude protein extract. Wash the crude protein extract three times with water: add 200ml of pure water to suspend, stir, stand, and filter; after repeating this three times, the precipitate is freeze-dried to obtain the target protein BD-2.
  • the second method column chromatography
  • the crude protein solution A was purified by HiTrap Q FF 16/10, HiTrap Capto Q ImpRes, Capto Q ImpRes, HiTrap Capto Q, HiTrap DEAE and other anion exchange resin columns.
  • the eluent is a gradient elution of NaCl solution, plus 20mM NaH 2 PO 4 /Na 2 HPO 4 buffer (pH 8.0).
  • the eluate fractions were detected and combined by SDS-PAGE electrophoresis, and the combined eluate was centrifuged twice at 7000 rpm for 1 hour each; the supernatant was filtered with a 0.45 ⁇ m filter membrane, and the filtrates were combined.
  • the filtrate is concentrated by dialysis with water, the molecular weight cut-off of the dialysis bag is 10kD, and the inner liquid is freeze-dried to obtain the target protein BD-2.
  • the product protein BD-2 obtained by the two methods was confirmed to have the same amino acid sequence as the protein prepared in Example 4 through the same structural confirmation method as in Example 4.
  • the crude protein solution B obtained in Example 2 was purified by the following three methods:
  • the first method dialysis
  • the crude protein solution B is filtered with a 0.45 ⁇ m membrane, the filtrate is dialyzed with water, dialyzed for more than 72 hours, and the inner solution is freeze-dried to obtain the target protein BD-2.
  • Dialysis bag Molecular weight cut-off 0.5kD, 3.5kD, 5kD, 10kD
  • the second method column chromatography
  • the crude protein solution B was purified by HiTrap Q FF 16/10, HiTrap Capto Q ImpRes, Capto Q ImpRes, HiTrap Capto Q, HiTrap DEAE and other anion exchange resin columns.
  • the eluent is a gradient elution of NaCl solution, plus 20mM NaH 2 PO 4 /Na 2 HPO 4 buffer (pH 8.0).
  • the eluate fractions were detected and combined by SDS-PAGE electrophoresis, and the combined eluate was centrifuged twice at 7000 rpm for 1 hour each; the supernatant was filtered with a 0.45 ⁇ m filter membrane, and the filtrates were combined.
  • the filtrate is concentrated by dialysis with water, the molecular weight cut-off of the dialysis bag is 10kD, and the inner liquid is freeze-dried to obtain the target protein BD-2.
  • the third method salting out
  • the crude protein solution B is placed in a container with stirring for two salting out: slowly add ammonium sulfate saturated solution along the wall to make the final concentration of ammonium sulfate 25% or 50%, the protein will precipitate during the salting out process, wait until the salting out is complete , Filter to complete the first salting out; add 400ml of pure water to the precipitate to suspend, again slowly add a saturated solution of ammonium sulfate along the wall to make the final concentration of ammonium sulfate 25%, perform the second salting out, filter, the precipitation is Crude protein extract. Wash the crude protein extract three times with water: add 200ml of pure water to suspend, stir, stand, and filter; after repeating this three times, the precipitate is freeze-dried to obtain the target protein BD-2.
  • the product protein BD-2 obtained by the three methods was confirmed to have the same amino acid sequence as the protein prepared in Example 4 through the same structural confirmation method as in Example 4.
  • the crude protein solution C obtained in Example 3 was purified by the following two methods:
  • the first method microfiltration membrane technology
  • the crude protein solution C is purified by microfiltration membrane technology: first use 1500nm or 1000nm ceramic membrane cores for solid-liquid separation; discard the inner liquid, and then use 20nm or 50nm ceramic membrane cores for repeated microfiltration to remove urea; secondary microfiltration The filtered inner liquid is freeze-dried to obtain the target protein BD-2.
  • the second method salting out
  • the crude protein solution C is placed in a stirred container for two salting out: slowly add saturated ammonium sulfate solution along the wall to make the final concentration of ammonium sulfate 25%. During the salting-out process, the protein will precipitate. After the salting-out is complete, filter it. Complete the first salting out; add 400ml of pure water to the precipitate to suspend, and then slowly add ammonium sulfate saturated solution along the wall to make the final concentration of ammonium sulfate 25%, perform the second salting out, filter, and the precipitate is the crude protein extraction Things. Wash the crude protein extract three times with water: add 200ml of pure water to suspend, stir, stand, and filter; after repeating this three times, the precipitate is freeze-dried to obtain the target protein BD-2.
  • the product protein BD-2 obtained by the two methods was confirmed to have the same amino acid sequence as the protein prepared in Example 4 through the same structural confirmation method as in Example 4.
  • Model group yeast fever model
  • Positive control group Aspirin 300mg/kg group
  • Protein BD-2 10mg/kg group, 50mg/kg group.
  • Preparation of experimental animals After the experimental animals have been adapted to the experimental environment (temperature 22°C ⁇ 2°C, relative humidity 50% ⁇ 2%) for 1 day, they are pre-adapted to measure rectal temperature at 8:00 and 15:00, respectively. The animals were fasted for the first 12 hours without water, and the animals were allowed to empty their feces before measuring the rectal temperature. Before each temperature measurement, apply petroleum jelly to the probe of the electronic thermometer and insert it into the rat rectum 2cm (can be marked at 2cm to ensure the same depth of insertion each time), and record the body temperature after the reading is stable.
  • Subcutaneous injection of dry yeast to replicate the rat fever model measure the rat's body temperature before modeling, select qualified rats with a body temperature of 36.2-37.3 °C, and randomly divide them into groups, each with 8 rats. After oral administration of aspirin and different doses of protein BD-2, immediately subcutaneously injected 20% yeast suspension (10ml/kg), and the normal control group was injected subcutaneously with an equal volume of normal saline. After 2 hours, the rats' body temperature was monitored at intervals of 2 hours. The body temperature was monitored once for a total of 8 hours. Statistics:
  • the positive tool drug aspirin group can effectively inhibit the increase in body temperature of model rats at 2 hours, 4 hours, 6 hours and 8 hours after modeling. Compared with the model group, P ⁇ 0.05, there is a statistical difference. The positive tool drug aspirin Stable performance.
  • LPS lipopolysaccharide
  • SIGMA L-2880 aspirin
  • SIGMA A2093 protein BD-2
  • Model group lipopolysaccharide fever model
  • Positive control group Aspirin 300mg/kg group
  • Protein BD-2 10mg/kg group, 50mg/kg group.
  • Lipopolysaccharide was injected into the abdominal cavity to replicate the rat fever model.
  • Preparation of experimental animals After the experimental animals have been adapted to the experimental environment (temperature 22°C ⁇ 2°C, relative humidity 50% ⁇ 2%) for 1 day, they shall be pre-adapted to the operation of measuring rectal temperature at 8:00 and 15:00 respectively, before the experiment Fasting for 12 hours without water, let the animals empty their feces before measuring the rectal temperature. Before each temperature measurement, apply petroleum jelly to the probe of the electronic thermometer and insert it into the rat rectum 2cm (can be marked at 2cm to ensure the same depth of insertion each time), and record the body temperature after the reading is stable.
  • Intraperitoneal injection of lipopolysaccharide to replicate the rat fever model measure the rat's body temperature before modeling, and select qualified rats with a body temperature of 36.2-37.3 °C, and randomly group them into groups of 8 rats.
  • lipopolysaccharide (20 ⁇ g/kg, 2ml/kg) was injected intraperitoneally immediately, and the normal control group was injected intraperitoneally with an equal volume of normal saline. After 2 hours, the rats' body temperature was monitored for a total of 8 hours.
  • the positive tool drug aspirin group can effectively inhibit the increase in body temperature of model rats at 2 hours, 4 hours, 6 hours and 8 hours after modeling. Compared with the model group, P ⁇ 0.05, there is a statistical difference, the positive tool drug performance More stable.
  • the BD-2 10mg/kg dose group had a tendency to lower the body temperature of the model rats at 2 and 8 hours after modeling, but there was no statistical significance.
  • Pilocarpine HCl PLO, pilocarpine, pilocarpine hydrochloride
  • Diazepam diazepam tablets
  • protein BD-2 PLO, pilocarpine, pilocarpine hydrochloride
  • Diazepam diazepam tablets
  • protein BD-2 PLO, pilocarpine, pilocarpine hydrochloride
  • Diazepam diazepam tablets
  • protein BD-2 protein BD-2.
  • Diazepam (Diazepam) 2mg/kg group;
  • Protein BD-2 50mg/kg group, 200mg/kg group.
  • PLO-225mg/kg (molding agent) was intraperitoneally injected 1 hour after gavage of the test drug on the day of modeling, and the positive drug was administered once 20 minutes before modeling. Observe for 30 minutes after PLO injection.
  • Level of seizure Refer to Racine grading standard: Level 0: No reaction; Level I: Twitching of facial muscles or the corners of the mouth; Level II: Nodding; Level III: Twitching of one limb; Level IV: Rigidity or twitching of the whole body ; Grade V: generalized epilepsy (generalized tonic convulsive seizures).
  • PTZ Pentylenetetrazol
  • Retigabine Protein BD-2.
  • Protein BD-2 50mg/kg group, 200mg/kg group.
  • Level of seizure Refer to Racine grading standard: Level 0: No reaction; Level I: Twitching of facial muscles or the corners of the mouth; Level II: Nodding; Level III: Twitching of one limb; Level IV: Rigidity or twitching of the whole body ; Grade V: full-blown epilepsy (generalized tonic convulsive seizures).
  • Drugs and reagents Mucosultan (ambroxol hydrochloride tablets), phenol red, sodium bicarbonate, protein BD-2;
  • centrifuge Sigma-3K15 type
  • balance XS105DU type
  • enzyme label tester BIO-TEK type
  • Protein BD-2 20mg/kg group, 50mg/kg group.
  • mice were sacrificed by neck removal, which were taken from the subthyroid cartilage.
  • To a segment of the trachea before the trachea branch put the trachea into 3ml of 5% NaHCO 3 solution and let stand for 3 hours, take 1ml of the supernatant, centrifuge at 3000rpm for 5 minutes, measure and record the absorbance at 546nm. Calculate the excretion of phenol red according to the standard curve of phenol red. The results are shown in Table 7.
  • the BD-2 20mg/kg dose group showed an upward trend in the excretion of phenol red, but it was not statistically significant.
  • Drugs and reagents dextromethorphan hydrobromide, ammonia, 0.2% CMC-Na, protein BD-2;
  • Apparatus Compressed atomizer (403T type), balance (XS105DU type).
  • Protein BD-2 20mg/kg group, 50mg/kg group.
  • Dextromethorphan and different doses of protein BD-2 were given orally in groups.
  • the solvent control group was given the same volume of distilled water. After 1 hour, it was placed in a sealed box and atomized with 10% ammonia water for 10 seconds. Zhong, then observe and record the incubation period of cough in mice and the number of coughs within 2 minutes.
  • the incubation period of cough refers to the number of seconds from the start of the atomization of ammonia to the occurrence of cough.
  • the performance of coughing in mice is based on contraction of the abdominal muscles (breast reduction) and opening of the mouth at the same time. Calculate the mean and standard error of each group of data, use TTEST to compare the model group with other groups, and P ⁇ 0.05 is considered as a significant difference.
  • Protein BD-2 50mg/kg group, 200mg/kg group.
  • the experimental animals were orally given aspirin 300mg/kg, protein BD-2 50mg/kg, 200mg/kg, and the administration volume was 10ml/kg one hour in advance; then 0.6% acetic acid solution was injected intraperitoneally and observed within 15 minutes The incubation period (seconds) and frequency of animal writhing.
  • mice The 0.6% acetic acid solution was injected into the abdominal cavity of mice, which caused deep and long-lasting painful stimulation, which caused the mice to have a writhing response (the abdomen was contracted into an "S" shape, the trunk and hind legs were stretched, the buttocks were raised and wriggled. Row).
  • the incubation time and the number of times the mice began to writhe were used as the pain response index to determine whether the test sample has analgesic effect.
  • the results of this experiment show:
  • Aspirin 300mg/kg can significantly delay the latency of writhing and reduce the frequency of writhing, and has a significant analgesic effect. Compared with the model group, P ⁇ 0.05, which is statistically significant.
  • BD-2 50mg/kg and 200mg/kg dose groups can significantly reduce the number of writhing times in mice. Compared with the model group, P ⁇ 0.05, which is statistically significant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

La présente invention concerne une kératine BD-2, une molécule d'acide nucléique codant pour celle-ci, un vecteur d'expression de celle-ci, une cellule hôte de celle-ci, et une composition pharmaceutique comprenant la kératine. La kératine BD-2 peut être utilisée pour préparer des médicaments antipyrétiques et analgésiques, antitussifs et expectorants, et anti-épileptiques.
PCT/CN2020/124327 2019-10-28 2020-10-28 Kératine bd-2, son procédé de préparation, composition pharmaceutique la comprenant et son utilisation WO2021083191A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911028748.1 2019-10-28
CN201911028748.1A CN112724232B (zh) 2019-10-28 2019-10-28 一种角蛋白bd-2、制法和其药物组合物与用途

Publications (1)

Publication Number Publication Date
WO2021083191A1 true WO2021083191A1 (fr) 2021-05-06

Family

ID=75589451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/124327 WO2021083191A1 (fr) 2019-10-28 2020-10-28 Kératine bd-2, son procédé de préparation, composition pharmaceutique la comprenant et son utilisation

Country Status (2)

Country Link
CN (1) CN112724232B (fr)
WO (1) WO2021083191A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
CN1324859A (zh) * 2000-05-24 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人角蛋白45.87和编码这种多肽的多核苷酸
CN102993291A (zh) * 2012-09-29 2013-03-27 乌仁套迪 双峰驼角蛋白、编码基因及其获取方法
CN109078023A (zh) * 2018-09-17 2018-12-25 南京中医药大学 一种角质类中药有效部位及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101647814A (zh) * 2008-08-13 2010-02-17 北京凯瑞创新医药科技有限公司 一种动物角的仿生酶解产物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
CN1324859A (zh) * 2000-05-24 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人角蛋白45.87和编码这种多肽的多核苷酸
CN102993291A (zh) * 2012-09-29 2013-03-27 乌仁套迪 双峰驼角蛋白、编码基因及其获取方法
CN109078023A (zh) * 2018-09-17 2018-12-25 南京中医药大学 一种角质类中药有效部位及其制备方法与应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Nucleotide 9 June 2008 (2008-06-09), ANONYMOUS: "Bos taurus keratin 34, mRNA (cDNA clone MGC:139887 IMAGE:8284533), complete cds", XP055806867, retrieved from NCBI Database accession no. BC118281 *
WU HONGXING, CHEN JINGGUO , LI ZHENHUA: "Effect of Antelope Horn Decoction on Serum TNF-α and IL-6 in Children with Persistent Fever", WU HONGXING, CHEN JINGGUO , LI ZHENHUA, vol. 27, no. 14, 31 July 2018 (2018-07-31), pages 79 - 80, XP055806911, ISSN: 1007-8517 *
ZHANG LONGFEI , HU JINGHONG , ZHANG YONGQING: "Research Overview of the Pharmacological Action of Cornu Saigae Tataricae", CHINA MEDICAL HERALD, vol. 10, no. 28, 5 October 2013 (2013-10-05), pages 23 - 26+33, XP055806914, ISSN: 1673-7210 *

Also Published As

Publication number Publication date
CN112724232B (zh) 2023-09-26
CN112724232A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
WO2021083201A1 (fr) Kératine bd-10, son procédé de préparation, et composition pharmaceutique de celle-ci, et son utilisation
WO2021083203A1 (fr) Kératine bd-13, procédé de préparation, composition pharmaceutique et utilisation de celle-ci
WO2021083206A1 (fr) Kératine bd-17, son procédé de préparation, et composition pharmaceutique et son utilisation
WO2021083190A1 (fr) Kératine bd-1, procédé de préparation, ainsi que composition pharmaceutique et utilisation de celle-ci
WO2021083202A1 (fr) Kératine bd-11, procédé de préparation et composition pharmaceutique et utilisation de celle-ci
WO2021083200A1 (fr) Kératine bd-6, procédé de préparation, composition pharmaceutique et utilisation associée
WO2021083191A1 (fr) Kératine bd-2, son procédé de préparation, composition pharmaceutique la comprenant et son utilisation
WO2021083193A1 (fr) Kératine bd-4, procédé de préparation et composition pharmaceutique et utilisation de celle-ci
WO2021083198A1 (fr) Kératine bd-5, procédé de préparation et composition pharmaceutique et utilisation de celle-ci
WO2021083205A1 (fr) Kératine bd-15, procédé de préparation et composition pharmaceutique et utilisation correspondante
WO2021083192A1 (fr) Kératine bd-3, son procédé de préparation, et composition pharmaceutique et son utilisation
WO2021083204A1 (fr) Kératine bd-14, procédé de préparation, composition pharmaceutique et utilisation de celle-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20881597

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20881597

Country of ref document: EP

Kind code of ref document: A1